Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported a net loss of $3.0 million for the fourth quarter of 2025, a reduction from the $4.2 million loss recorded in the same period a year earlier. The company’s earnings statement shows that the loss improvement is largely attributable to disciplined cost management, with research and development expenses falling to $0.7 million from $1.5 million and general and administrative costs decreasing to $2.4 million from $2.7 million.
For the full year 2025, Cadrenal posted a net loss of $10.2 million, a modest narrowing from the $10.7 million loss reported for 2024. The company’s total operating expenses for the year were $3.1 million, reflecting a 42 % reduction in R&D spending and a 11 % cut in G&A costs, underscoring a strategic shift toward more efficient resource allocation as the company focuses on its flagship CAD‑1005 program.
Cash and cash equivalents stood at $4.0 million as of December 31 2025, with a quarterly burn rate of approximately $3.3 million. Cadrenal has no revenue streams to offset its operating losses, and management has indicated that it is actively evaluating financing options and strategic alternatives to extend its runway and support ongoing clinical development.
The company’s CAD‑1005 program, a first‑in‑class selective 12‑LOX inhibitor for heparin‑induced thrombocytopenia (HIT), has made significant progress. Positive Phase 2 data were presented, and an End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration was held on March 26 2026. CAD‑1005 has received Orphan Drug and Fast Track designations, positioning it for a potentially accelerated regulatory pathway.
Beyond CAD‑1005, Cadrenal’s pipeline includes tecarfarin for chronic anticoagulation and frunexian for acute care settings. The company was incorporated in 2022 and has shifted its primary strategy to CAD‑1005 following an asset acquisition in December 2025, reflecting a concentrated focus on a single, high‑potential therapeutic area.
The financial results highlight the company’s cash‑constrained environment and the urgency of securing additional capital. While the modest narrowing of the full‑year loss and the reduction in operating expenses signal disciplined management, the lack of revenue and the high burn rate underscore the risk that Cadrenal will need to raise funds or achieve a breakthrough in its clinical program to sustain operations and realize future revenue streams.
revised_sentiment_rating:-3
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.